Bill Anderson's replacement as chief executive of Roche Pharmaceuticals has been announced, with head of global product strategy Teresa Graham stepping up into the role.
Ken Frazier's final appearance on Merck & Co's financial results call as chief executive was a muted affair, as the company reported lower-than-expected revenues dragged down as the pan
Boehringer Ingelheim invested €3.7 billion on R&D last year, the highest spend in its history, as it mobilised its scientists to seek out new therapies for COVID-19.
GlaxoSmithKline saw a recovery in its vaccine sales in the third quarter after a big hit in the second as a result of the COVID-19 pandemic, putting it back on course to meet the lower end
It has been five years since Lexicon Pharma's type 1 diabetes therapy, Zynquista, was rejected by the FDA, and it may struggle to have a better outcome at its second attempt.